<DOC>
	<DOCNO>NCT00480545</DOCNO>
	<brief_summary>Indirect evidence suggest hormonal fluctuation menstrual cycle also affect bleed clot system . This study look two sensitive laboratory test four time point menstrual cycle determine natural variation coagulation platelet function . Laboratory test healthy subject compare woman von Willebrand 's disorder type 1 , bleed disorder . In future , laboratory test may help diagnosis bleed clot disorder design treatment woman abnormal menstrual bleeding .</brief_summary>
	<brief_title>Changes Bleeding Clotting During Menstrual Cycle</brief_title>
	<detailed_description>Von Willebrand disease ( VWD ) common hereditary bleeding disorder , occur 1-2 % population . Menorrhagia , heavy menstrual bleeding , occur majority woman von Willebrand disease ( VWD ) adversely affect quality life . The American College Obstetrics Gynecology recommend woman heavy menstrual bleeding diagnostic test VWD . Unfortunately , diagnosis VWD woman menorrhagia difficult due fluctuation hemostatic protein level menstrual cycle . The lack useful coagulation assay also limit scope pharmacokinetic study comparative clinical trial need determine best clinical practice woman VWD . Two new assay system offer possibility increase sensitivity physiologic variation coagulation fibrinolysis . The calibrated automate thrombin generation assay ( TG ) , estimation endogenous thrombin potential ( ETP ) , measure generation thrombin throughout entire process coagulation appear sensitive small change level coagulation protein . Thromboelastography ( TEG ) record clot formation dissolution whole blood sample provide good marker fibrinolysis . We propose TG TEG sensitive traditional coagulation assay detect physiologic variation hemostasis menstrual cycle accurately diagnose VWD . This single-institution pilot study identify trend worthy exploration large multi-institutional study . Our primary objective describe characteristic TG TEG 4 time point menstrual cycle ( day 0-3 , 7-10 , 14-17 , 21-24 ) . Our secondary goal quantify effect VWD TG TEG time point menstrual cycle compare traditional coagulation assay . This single-institution pilot study total 40 subject : 20 healthy woman 20 woman VWD . Subjects must female age 18 50 year , regular menstrual period , pregnant . Women take hormonal therapy , anti-fibrinolytic therapy , hemostatic agent anti-platelet agent , eligible participation . Subjects give tampon and/or pad use one menstrual cycle . Study participation involve brief interview , completion questionnaire pictorial chart one menstrual cycle , blood drawn 4 time point one menstrual cycle . Blood sample collect TG TEG standard assay coagulation fibrinolysis . TG TEG measurement compare standard measure coagulation , fibrinolysis , platelet activation marker . Serum visit day 21-24 test progesterone Bhcg confirm ovulation exclude pregnancy . All assay perform Gulf States Hemophilia &amp; Thrombophilia coagulation laboratory . This study result improve capability diagnose woman VWD menstrual cycle . These new assay may useful rational design therapeutic agent clinical trial . In addition , physiologic basis variation coagulation menstrual cycle explore future study use assay system .</detailed_description>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<criteria>Must female Aged 18 50 year , regular menstrual cycle . Healthy volunteer woman von Willebrand 's disorder recruit . Pregnancy Use hormonal therapy include birth control pill Use hemostatic agent DDAVP antiplatelet agent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Women bleed disorder</keyword>
	<keyword>Menstrual cycle</keyword>
	<keyword>Women</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>